Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 7Colorectal Neoplasms 4Stomach Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Meningeal Neoplasms 1HER2-positive Breast Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Brain Neoplasms 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Trastuzumab 3Sugammadex 2Neostigmine 2Cisplatin 2valrubicin 1tucatinib 1pembrolizumab 1niraparib 1enfortumab vedotin 1avelumab 1atezolizumab 1Surveys and Questionnaires 1Sunitinib 1Standard of Care 1Rocuronium 1Pemetrexed 1Paclitaxel 1Nephroureterectomy 1Neoadjuvant Therapy 1Mitomycin 1Lymph Node Excision 1Glycopyrrolate 1Gemcitabine 1GSK-3326595 1Fulvestrant 1Docetaxel 1Cetuximab 1Afatinib 1Administration, Intravesical 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urologic Neoplasms × tucatinib × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡